Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D
CONCLUSIONS: Among patients with CKD stages 3-4, anti-osteoporotic drugs may reduce the risk of vertebral fracture in low certainty evidence. Anti-osteoporotic drugs make little or no difference to the risk of clinical fracture and adverse events in moderate certainty evidence. Among patients with CKD stages 5 and 5D, it is uncertain whether anti-osteoporotic drug reduces the risk of clinical fracture and death because the certainty of this evidence is very low. Anti-osteoporotic drug may slightly improve the BMD at the lumbar spine in low certainty evidence. It is uncertain whether anti-osteoporotic drug improves the BMD at the femoral neck because the certainty of this evidence is very low. Larger studies including men, paediatric patients or individuals with unstable CKD-mineral and bone disorder are required to assess the effect of each anti-osteoporotic drug at each stage of CKD.PMID:34231877 | DOI:10.1002/14651858.CD013424.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Takashi Hara Yasukazu Hijikata Yukiko Matsubara Norio Watanabe Source Type: research
More News: Chronic Kidney Disease | Clinical Trials | Conferences | Databases & Libraries | DEXA Scan | Dialysis | Evista | Forteo | General Medicine | Kidney Transplant | Kidney Transplantation | Orthopaedics | Osteoporosis | Pediatrics | Radiography | Study | Transplant Surgery | Transplants | Urology & Nephrology | Women | Xgeva